The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

The FDA said it's taking action to protect patients from unapproved animal-derived thyroid medications and expressed concern ...

Drugmaker Eli Lilly says their oral, daily GLP-1 pill, orforglipron, may offer similar weight loss results as weekly GLP-1 ...

An observational study of 160,000 patients with diabetes taking GLP-1 drugs finds no heightened risk for retinopathy ...

Insurance companies are increasingly restricting coverage for GLP-1 medications, impacting patient access and affordability.

In the first Phase 3 trial of its once-daily oral GLP-1 pill in people with obesity, drugmaker Eli Lilly said Thursday that ...

One popular health platforms is promoting GLP-1 microdosing for weight loss: But how safe and effective is this approach?

Drugmaker Eli Lilly says after successful results in a phase 3 clinical trial, it expects to submit a GLP-1 weight loss pill ...

Results from a Phase II trial (NCT06640972) showed that patients treated with RDX-002 experienced significant reductions in ...

Eli Lilly will seek regulatory approval for its next-generation weight-loss pill by year-end, based on data that suggests it ...

The weight loss conversation has been transformed in recent years by the rise of GLP-1 medications—drugs originally developed for diabetes that are now being used to help people lose significant ...

GLP-1 weight-loss drugs have already taken the Europe storm, altering consumer eating habits. Even the eating habits of GLP-1 ...